Leadership & Pay ·
Faeth Therapeutics, Inc. appointed Karen Vousden, Ph.D., as a Class II director effective September 11, 2026…
FTHFaeth Therapeutics, Inc.
Faeth Therapeutics, Inc. appointed Karen Vousden, Ph.D., as a Class II director effective September 11, 2026, increasing the Board size from five to six members. Dr. Vousden, a co-founder and cancer biologist with extensive experience at The Francis Crick Institute and Cancer Research UK, will also serve on the Compensation Committee. Her appointment includes an initial equity grant of options for 25,000 shares vesting over three years. Faeth Therapeutics is a biopharmaceutical company focused on developing therapies targeting p53-related cancers.